Norris Medicines Ltd
Incorporated in 1990, Norris Medicines Ltd manufacturers Injections and Medicinal formulations
- Market Cap ₹ 17.2 Cr.
- Current Price ₹ 17.2
- High / Low ₹ 27.7 / 12.8
- Stock P/E
- Book Value ₹ -14.9
- Dividend Yield 0.00 %
- ROCE -10.1 %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -5.78% over past five years.
- Promoter holding is low: 34.0%
- Debtor days have increased from 68.4 to 88.4 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Services Services Commercial Services & Supplies Trading & Distributors
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
20.70 | 18.68 | 18.86 | 20.46 | 13.57 | 16.26 | 7.84 | 12.25 | 9.44 | 8.36 | 5.64 | 5.82 | 6.56 | |
21.76 | 16.97 | 18.03 | 20.46 | 15.49 | 16.87 | 10.00 | 14.00 | 9.52 | 7.43 | 5.81 | 6.08 | 6.77 | |
Operating Profit | -1.06 | 1.71 | 0.83 | 0.00 | -1.92 | -0.61 | -2.16 | -1.75 | -0.08 | 0.93 | -0.17 | -0.26 | -0.21 |
OPM % | -5.12% | 9.15% | 4.40% | 0.00% | -14.15% | -3.75% | -27.55% | -14.29% | -0.85% | 11.12% | -3.01% | -4.47% | -3.20% |
0.12 | 0.15 | 0.30 | 0.06 | 0.14 | 0.04 | 0.09 | 0.05 | 0.03 | 0.01 | 0.01 | 0.06 | 0.07 | |
Interest | 0.45 | 0.54 | 0.67 | 0.60 | 0.70 | 0.73 | 0.88 | 1.63 | 1.48 | 1.50 | 0.37 | 0.44 | 0.46 |
Depreciation | 1.17 | 1.31 | 0.60 | 0.65 | 0.71 | 0.71 | 0.73 | 0.67 | 0.66 | 0.63 | 0.57 | 0.54 | 0.52 |
Profit before tax | -2.56 | 0.01 | -0.14 | -1.19 | -3.19 | -2.01 | -3.68 | -4.00 | -2.19 | -1.19 | -1.10 | -1.18 | -1.12 |
Tax % | -42.97% | 10,500.00% | -128.57% | -35.29% | -21.00% | -16.42% | -22.83% | 24.25% | 49.32% | 47.06% | 8.18% | 5.08% | |
-1.45 | -1.04 | 0.04 | -0.77 | -2.51 | -1.68 | -2.84 | -4.96 | -3.26 | -1.75 | -1.19 | -1.24 | -1.18 | |
EPS in Rs | -1.45 | -1.04 | 0.04 | -0.77 | -2.51 | -1.68 | -2.84 | -4.96 | -3.26 | -1.75 | -1.19 | -1.24 | -1.18 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | -11% |
5 Years: | -6% |
3 Years: | -15% |
TTM: | 21% |
Compounded Profit Growth | |
---|---|
10 Years: | -2% |
5 Years: | 9% |
3 Years: | 17% |
TTM: | -24% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 26% |
3 Years: | 22% |
1 Year: | 27% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | % |
Balance Sheet
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 |
Reserves | -3.58 | -4.63 | -4.60 | -5.36 | -7.88 | -9.55 | -12.39 | -17.36 | -20.62 | -22.37 | -23.56 | -24.79 |
7.52 | 8.16 | 7.51 | 7.57 | 7.71 | 11.24 | 17.92 | 15.52 | 21.08 | 21.40 | 21.52 | 21.58 | |
7.45 | 4.69 | 5.06 | 9.90 | 10.92 | 8.76 | 5.10 | 11.69 | 3.80 | 4.72 | 6.29 | 7.09 | |
Total Liabilities | 21.32 | 18.15 | 17.90 | 22.04 | 20.68 | 20.38 | 20.56 | 19.78 | 14.19 | 13.68 | 14.18 | 13.81 |
8.97 | 8.61 | 8.34 | 9.97 | 9.32 | 8.90 | 8.25 | 7.67 | 7.07 | 6.47 | 5.79 | 5.27 | |
CWIP | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
12.24 | 9.53 | 9.55 | 12.06 | 11.35 | 11.47 | 12.30 | 12.10 | 7.11 | 7.20 | 8.38 | 8.53 | |
Total Assets | 21.32 | 18.15 | 17.90 | 22.04 | 20.68 | 20.38 | 20.56 | 19.78 | 14.19 | 13.68 | 14.18 | 13.81 |
Cash Flows
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1.44 | -1.43 | 1.35 | -0.96 | 0.80 | -1.92 | -2.88 | 1.11 | -1.01 | 1.20 | 0.17 | 0.30 | |
-1.75 | -0.88 | -0.34 | -2.05 | -0.08 | -0.29 | 0.00 | -0.06 | -0.09 | -0.02 | 0.05 | 0.58 | |
0.02 | 0.10 | -1.32 | 3.16 | -0.66 | 2.18 | 2.86 | -1.09 | 1.10 | -1.18 | -0.20 | -0.49 | |
Net Cash Flow | -0.28 | -2.21 | -0.31 | 0.15 | 0.06 | -0.02 | -0.02 | -0.04 | 0.00 | 0.00 | 0.02 | 0.40 |
Ratios
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 91.34 | 73.66 | 53.61 | 84.20 | 66.44 | 67.57 | 128.49 | 53.33 | 42.15 | 48.03 | 68.60 | 88.43 |
Inventory Days | 74.17 | 100.05 | 134.23 | 129.50 | 238.53 | 134.81 | 323.82 | 212.99 | 157.45 | 347.62 | 594.15 | 436.94 |
Days Payable | 151.02 | 111.66 | 99.30 | 125.29 | 252.40 | 139.83 | 233.37 | 218.83 | 86.53 | 149.91 | 244.25 | 320.57 |
Cash Conversion Cycle | 14.50 | 62.06 | 88.54 | 88.41 | 52.56 | 62.55 | 218.94 | 47.49 | 113.06 | 245.73 | 418.51 | 204.80 |
Working Capital Days | 12.87 | 27.75 | 34.84 | -16.06 | -91.18 | -32.55 | -30.73 | -103.69 | -97.82 | -122.25 | -202.56 | -241.45 |
ROCE % | 4.02% | 4.03% | -4.08% | -22.92% | -11.97% | -20.68% | -20.13% | -7.68% | 3.20% | -8.43% | -10.14% |
Documents
Announcements
- Outcome Of Board Meeting Held On Thursday, 14Th August 2025 Pursuant To Regulation 30 And Regulation 33 Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015. 14 Aug
-
Board Meeting Outcome for Outcome Of Board Meeting Held On Thursday, 14Th August 2025 Pursuant To Regulation 30 And Regulation 33 Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015.
14 Aug - Approved unaudited Q1 FY2026 financial results for Norris Medicines Limited.
-
Board Meeting Intimation for Intimation Under Regulation 29 Of SEBI Listing Obligation And Disclosure Requirements, 2015 For Holding Board Meeting For Approval Of Un-Audited Financial Results For The Quarter Ended June 30Th, 2025 And Other Matters.
11 Aug - Board meeting on Aug 14 to approve Q1 June 2025 un-audited financial results.
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 18 Jul
-
Closure of Trading Window
27 Jun - Trading window closed from July 1, 2025, till 48 hours after June quarter results announcement.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2000
from bse
-
Financial Year 1998
from bse
Business Overview:[1]
Company is in Health Care Industry and does contract manufacturing and Loan License Manufacturing for pharma companies.